157 related articles for article (PubMed ID: 10883887)
21. A monoclonal antibody specific for human thymidine kinase 1.
Zhang F; Shao X; Li H; Robison JG; Murray BK; O'Neill KL
Hybridoma; 2001 Feb; 20(1):25-34. PubMed ID: 11289224
[TBL] [Abstract][Full Text] [Related]
22. Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes.
Wang Z; Zhang W; Huo B; Dong L; Zhang J
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32202305
[TBL] [Abstract][Full Text] [Related]
23. Aptamer-Based Sandwich Assay for Measurement of Thymidine Kinase 1 in Serum of Cancerous Patients.
Nazari M; Gargari SLM; Sahebghadam Lotfi A; Rassaee MJ; Taheri RA
Biochemistry; 2019 May; 58(18):2373-2383. PubMed ID: 30900869
[TBL] [Abstract][Full Text] [Related]
24. AroCell TK 210 ELISA for determination of TK1 protein: age-related reference ranges and comparison with other TK1 assays.
Kumar JK; Holmgren S; Levedahl KH; Höglund M; Venge P; Eriksson S
Biotechniques; 2020 Jun; 68(6):334-341. PubMed ID: 32336110
[TBL] [Abstract][Full Text] [Related]
25. Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas.
Jaamaa S; Nevala R; Jagarlamudi K; Tukiainen E; Blomqvist C; Sampo M
Anticancer Res; 2022 Mar; 42(3):1509-1515. PubMed ID: 35220246
[TBL] [Abstract][Full Text] [Related]
26. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas.
He Q; Mao Y; Wu J; Decker C; Merza M; Wang N; Eriksson S; Castro J; Skog S
Int J Oncol; 2004 Oct; 25(4):945-53. PubMed ID: 15375544
[TBL] [Abstract][Full Text] [Related]
27. Development of a gold nanoparticle-based lateral flow immunochromatographic assay for the rapid and quantitative detection of thymidine kinase 1 in human serum.
Ye L; Xu X; Qu A; Kuang H; Liu L; Xu C
J Pharm Biomed Anal; 2024 Aug; 245():116146. PubMed ID: 38631069
[TBL] [Abstract][Full Text] [Related]
28. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.
Bjöhle J; Bergqvist J; Gronowitz JS; Johansson H; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Söderberg M; Sundquist M; Walz TM; Fernö M; Bergh J; Hatschek T
Breast Cancer Res Treat; 2013 Jun; 139(3):751-8. PubMed ID: 23736998
[TBL] [Abstract][Full Text] [Related]
29. Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy.
Bolayirli M; Papila C; Korkmaz GG; Papila B; Aydoğan F; Karataş A; Uzun H
J Clin Lab Anal; 2013 May; 27(3):220-6. PubMed ID: 23686779
[TBL] [Abstract][Full Text] [Related]
30. Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma.
Wu BJ; Li WP; Qian C; Ding W; Zhou ZW; Jiang H
Tumour Biol; 2013 Apr; 34(2):643-8. PubMed ID: 23179401
[TBL] [Abstract][Full Text] [Related]
31. Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial.
McCartney A; Bonechi M; De Luca F; Biagioni C; Curigliano G; Moretti E; Minisini AM; Bergqvist M; Benelli M; Migliaccio I; Galardi F; Risi E; De Santo I; Romagnoli D; Biganzoli L; Di Leo A; Malorni L
Clin Cancer Res; 2020 May; 26(9):2131-2139. PubMed ID: 31937617
[TBL] [Abstract][Full Text] [Related]
32. Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer.
Carlsson L; Larsson A; Lindman H
Ups J Med Sci; 2009; 114(2):116-20. PubMed ID: 19396699
[TBL] [Abstract][Full Text] [Related]
33. Quaternary structures of recombinant, cellular, and serum forms of thymidine kinase 1 from dogs and humans.
Hanan S; Jagarlamudi KK; Liya W; Ellen H; Staffan E
BMC Biochem; 2012 Jun; 13():12. PubMed ID: 22741536
[TBL] [Abstract][Full Text] [Related]
34. The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer.
Zou L; Zhang PG; Zou S; Li Y; He Q
Int J Biol Markers; 2002; 17(2):135-40. PubMed ID: 12113581
[TBL] [Abstract][Full Text] [Related]
35. Clinical Applicability of the Proliferation Marker Thymidine Kinase 1 in Head and Neck Cancer Patients.
Meirovitz A; Gross M; Leibovici V; Sheva K; Popovzer A; Barak V
Anticancer Res; 2021 Feb; 41(2):1083-1087. PubMed ID: 33517319
[TBL] [Abstract][Full Text] [Related]
36. Expression and Clinical Significance of Cytokeratin-19 and Thymidine Kinase-1 in Advanced Gastrointestinal Cancer.
Du YY; Zhang QJ; Sun GP
Chin Med J (Engl); 2016 Sep; 129(18):2168-72. PubMed ID: 27625087
[TBL] [Abstract][Full Text] [Related]
37. Serum detection of thymidine kinase 1 as a means of early detection of lung cancer.
Alegre MM; Weyant MJ; Bennett DT; Yu JA; Ramsden MK; Elnaggar A; Robison RA; O'Neill KL
Anticancer Res; 2014 May; 34(5):2145-51. PubMed ID: 24778016
[TBL] [Abstract][Full Text] [Related]
38. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
Xi QP; Pu DH; Lu WN
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation.
He Q; Skog S; Wang N; Eriksson S; Tribukait B
Eur J Cell Biol; 1996 Jun; 70(2):117-24. PubMed ID: 8793383
[TBL] [Abstract][Full Text] [Related]
40. Microchip immunoaffinity electrophoresis of antibody-thymidine kinase 1 complex.
Pagaduan JV; Ramsden M; O'Neill K; Woolley AT
Electrophoresis; 2015 Mar; 36(5):813-7. PubMed ID: 25486911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
